compact biophotonic platform for drug allergy … · 2018-12-10 · compact biophotonic platform...
TRANSCRIPT
COMPACT BIOPHOTONIC PLATFORM FOR DRUGALLERGY DIAGNOSIS (COBIOPHAD)
Estrella Fernández1, Teresa Molina-Jiménez1, Sergi Morais1,2, Luís A. Tortajada-Genaro1,2, Rosa Puchades1,2, Ángel Maquieira1,2
Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM)1Universitat Politècnica de València-Universitat de València. Camino de vera s/n, 46022 Valencia.
2 Departamento de Química, Universitat Politècnica de València. Camino de vera s/n, 46022 Valencia.E-mail: [email protected]
Acknowledgements
The COBIOPHAD Project has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement No. 688448. It is an initiative of
the Photonics Public Private Partnership (www.photonics21.org)
References
[1] M. Blanca, A. Romano, M. J. Torres, J. Fernandez, C. Mayorga, J.
Rodriguez, P. Demoly, P. J. Bousquet, H. F. Merk, M. L. Sanz, H. Ott, M.
Atanaskovic. Update on the evaluation of hypersensitivity reactions to
betalactams. Allergy. 2009, vol. 64, 183-193.
[2] M. J. Torres, A. Romano, G. Celik, P. Demoly, D. A. Khan, E. Macy, M.
Park , K. Blumenthal, W. Aberer, M. Castells, A. Barbaud, C. Mayorga, P.
Bonadonna. Clinical and Translational Allergy. 2017, vol. 7, 1-13.
COBIOPHAD is organized on seven Work Packages
NOW FUTURE (COBIOPHAD)
WP1 comprises the development of the
hardware, firmware and software of the
biophotonic device based on Optical Disc Drive.
WP2 is focused on the design and
manufacturing of disc prototypes, based on a
centrifugal microfluidic system for fully
automated the assay.
WP3 addresses the collection of
human blood samples, synthesis of
structural determinants and high-
affinity anti-IgE.
WP4 aims at the integration of the
components and evaluation of the
analytical performance of the reagents,
disc and reader.
GOLD STANDARD:in vivo skin tests & provocation tests
• Good specificity (98-100%)• Invasive• Time consuming• Low sensitivity (61-70%)• High rate of false diagnosis with critical
consequences: risk of mortality• Uncomfortable for patients
CURRENT ALTERNATIVE:in vitro diagnostic methods (IVD)
• Minimally invasive• Developed with bulky autoanalyzers, based
on classical technologies• Low sensitivity (< 40%)• High detection threshold (>0.2kU/L)• Only for 5 BLCs• False positive and negative results• Expensive (test: 30€/allergen)
Quick & cheap IVD tests for specific IgEs / BLC hypersensitivity: highly demanded
solution to guarantee safe and sure diagnostics
COBIOPHAD is developing an innovative IVD solution based on compact disc technology
for diagnosis of IgE-mediated drug allergies
Current state
400um
WP1: DETECTORWP2:PLATFORMWP3: ASSAYWP4: INTEGRATION
WP5: VALIDATION ANDPRE-INDUSTRALIZATION
MARKETTECHNOLOGICAL INNOVATION
TRL4 TRL7
WP6: IP & DISSEMINATIONWP7: COORDINATION
• Low-cost device (detector manufacturing cost ~300 €)
• Low-cost consumables (~1 € per disc and ~0.3 €/allergen in
reagents)
• Autonomous, robust
• Broad range of scenarios: emergency and critical care units, allergy
departments
COBIOPHAD specifications:
• Sensitivity (80%) and detection limit below 0.1 kU/L
• High specificity ( 98%) simultaneous response to 10 BLCs
• Multiplexing capability (up to 10 samples per BLC or BLCs per
disc)
• Rapid, 30 minutes maximum total analysis time
Hypersensitivity to Beta-Lactams (BLCs)
BLCs antibiotics are the most dispensed in EU
50% or more of the total antibiotics consumption
Affects 2.5 million people in EU and causes 47% of drug anaphylaxis
Public health problem
Erroneous allergy
diagnosis, wrong
treatment
High costs of drug
allergy diagnosis
(~ 500 €/drug)
Hospitalization:
1750-4500 €/patient